Comparing two drug combos for advanced stomach cancer
Part of Cancer clinical trials.
This trial compares two treatments for advanced stomach cancer: fruquintinib plus paclitaxel versus ramucirumab plus paclitaxel. It aims to see which combination works better for patients who have already received certain therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach or gastroesophageal junction (GEJ) adenocarcinoma, confirmed by biopsy.
- Your cancer has spread to other parts of the body (advanced or metastatic).
- You are in relatively good health, with a performance status (ECOG) of 0 or 1, meaning you can carry out daily activities with little or no help.
- You have received treatment with either fruquintinib plus paclitaxel or the reference regimen (ramucirumab plus paclitaxel).
- Your medical records include key information like age, prior treatments, and disease details needed for the matching analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of paclitaxel polymeric micelles and fruquintinib capsules as a second-line treatment for patients with advanced gastric cancer whose first-line therapy with oxaliplatin and fluorouracil has stopped working. The goal is to see if this new drug combination can shrink tumors and how safe it is.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.